[go: up one dir, main page]

WO2002045687A2 - Topical alcoholic solution of a salicylic acid derivative and acemannan - Google Patents

Topical alcoholic solution of a salicylic acid derivative and acemannan Download PDF

Info

Publication number
WO2002045687A2
WO2002045687A2 PCT/GB2001/005380 GB0105380W WO0245687A2 WO 2002045687 A2 WO2002045687 A2 WO 2002045687A2 GB 0105380 W GB0105380 W GB 0105380W WO 0245687 A2 WO0245687 A2 WO 0245687A2
Authority
WO
WIPO (PCT)
Prior art keywords
salicylic acid
acemannan
solution
acid derivative
physiologically tolerable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2001/005380
Other languages
French (fr)
Other versions
WO2002045687A3 (en
Inventor
Henrik Steenfeldt-Foss
Per Stanley Thrane
Jo Klaveness
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NORWAY MEDICAL GROUP INT AS
Original Assignee
NORWAY MEDICAL GROUP INT AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NORWAY MEDICAL GROUP INT AS filed Critical NORWAY MEDICAL GROUP INT AS
Priority to EP01999356A priority Critical patent/EP1349540A2/en
Priority to AU2002218419A priority patent/AU2002218419A1/en
Publication of WO2002045687A2 publication Critical patent/WO2002045687A2/en
Publication of WO2002045687A3 publication Critical patent/WO2002045687A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • This invention relates to the use of topically applied salicylic acid derivative compositions in the treatment of herpes zoster in humans, in particular to the use of such compositions which are in liquid form and which further contain aloe vera or acemannan, an active component thereof .
  • the virus herpes zoster is a latent form of the virus responsible for chicken pox and causes the intractable and painful skin eruptions known as shingles which afflict many millions of the elderly in particular. Such painful occurrences are known as herpetic neuralgia, e.g. acute herpetic neuralgia and postherpetic neuralgia.
  • acetyl salicylic acid is a very well known anti-inflammatory which is normally administered orally in tablet form. While liquid compositions containing ASA, in particular alkanolic solutions of ASA, have been proposed, e.g. for treatment of muscle and joint pain, rheumatism, etc, in recent years liquid ASA formulations have fallen out of favour since ASA is susceptible to hydrolysis producing the irritant salicylic acid.
  • topically applied alcoholic solutions of ASA and acemannan are surprisingly effective in combatting herpetic neuralgia, in particular providing a level of pain relief to the patient .
  • the invention provides an alcoholic solution of a physiologically tolerable salicylic acid derivative and an acemannan for use in topical treatment of herpetic neuralgia.
  • the invention provides the use of a physiologically tolerable salicylic acid derivative, an alcohol and an acemannan for the manufacture of a topically applicable medicament for use in the treatment of herpetic neuralgia.
  • the invention provides a method of treatment of herpetic neuralgia in a human subject which method comprises applying to an affected area of the skin of said subject an analgesically effective amount of an alcoholic solution of a physiologically tolerable salicylic acid derivative and an acemannan.
  • the salicylic acid derivative used according to the invention may be any physiologically tolerable derivative having analgesic properties.
  • the salicylic acid derivative used in the present invention is preferably ASA, or a physiologically tolerable prodrug (e.g. glycolamide) or salt (e.g. a lysine salt) or ester form thereof or an analog thereof (e.g. a 4 or 5 substituted, for example a 4- and/or 5- nitro and/or methoxy acetyl salicylic acid) .
  • ASA physiologically tolerable prodrug
  • salt e.g. a lysine salt
  • ester form thereof e.g. a 4 or 5 substituted, for example a 4- and/or 5- nitro and/or methoxy acetyl salicylic acid
  • the salicylic acid derivative if used in salt form, will have as counterion a physiologically tolerable counterion, preferably an amino acid such as lysine.
  • a physiologically tolerable counterion preferably an amino acid such as lysine.
  • Other tolerable counterions include sodium and meglumine .
  • Suitable prodrug forms of ASA include esters which hydrolyse more rapidly in vivo than the acetyl group, e.g. compounds of formula
  • R ⁇ is _ 3 alkyl and R 2 is C ⁇ alkyl , 2 -hydroxy-ethyl or -CH 2 CONH 2 , e.g. -CH 2 CON (CH 3 ) 2 , -CH 2 CON (C 2 H 5 ) 2 , -CH 2 CON (iPr) 2 , -CH 2 CON (CH 3 ) CH 2 CH 2 OH and CH 2 CON (CH 3 ) CH 2 CONH 2 .
  • Acetyl salicylic acid is especially preferred.
  • compositions of the invention also contain acemannan, e.g. in the form of aloe vera. If aloe vera is used, it is preferably used in a pure gel state, although aloe vera in a slightly impure (e.g. at least 98% wt pure) may also be used. Acemannan as such may be used in place of aloe vera.
  • compositions of the invention may be in any topically applicable administration form which does not require rubbing of the affected skin, e.g. solutions, emulsions, dispersions, liposomal compositions, sprays, etc.
  • the compositions are in the form of solutions or liposome dispersions, particularly solutions .
  • compositions may contain transdermal uptake promoters, such as for example dimethylsulphoxide (DMSO) , dimethylformamide, dimethylacetamide, cycloalkanones, etc. (see US-A- 5164416 and EP-A-435436) .
  • transdermal uptake promoters such as for example dimethylsulphoxide (DMSO) , dimethylformamide, dimethylacetamide, cycloalkanones, etc. (see US-A- 5164416 and EP-A-435436) .
  • compositions contain an alcohol solvent for the salicylic acid derivative, e.g. a C ⁇ _ 6 alkanol, preferably a propanol, especially isopropanol.
  • an alcohol solvent for the salicylic acid derivative e.g. a C ⁇ _ 6 alkanol, preferably a propanol, especially isopropanol.
  • compositions of the invention preferably also contain a drying agent, e.g. an inorganic salt in anhydrous or partially hydrated form, so as to minimize the water content of the solvent phase .
  • a drying agent e.g. an inorganic salt in anhydrous or partially hydrated form
  • the drying agent is preferably a porous material which take up water into its pores or by surface adsorption. Alternatively, it may adsorb water by reaction or by hydration of an anhydrous or partially hydrated form of a crystalline substance with stable hydrated forms.
  • it may for example be a zeolite, e.g. a zeolite with a pore size of 4A or more, for example up to 10A (or where methanol is used as a solvent, a pore size of 3A) .
  • a zeolite having a pore size of up to 6A, more preferably up to 5A, e.g. 3 to 4A will be used.
  • Such zeolites are available commercially, e.g.
  • silica, alumina or silica-alumina or modified starches e.g. the hydrolysed starch graft copolymers proposed for use in diapers or used in gardening as water retainers - see also GB-A-2009201 and EP-A-74179
  • anhydrous or partially hydrated salts such as metal sulphates (e.g. magnesium sulphate or sodium sulphate) may alternatively be used.
  • Water retainers e.g.
  • modified starches developed in the 1980s by Henkel for diapers and sanitary pads (see the patent publications of Henkel) , and now used in gardening, are typified by "soil-moist", available from Sinclair, Linconshire, UK.
  • the water-adsorbers used should preferably be substantially water free when incorporated into the compositions of the invention.
  • Particle size is preferably 10 to 4000 ⁇ m, especially 50 to 2000 ⁇ m.
  • compositions of the invention further preferably contain a stabilizer, e.g. a polyol or polyalkylene oxide, for example glycerol, polyethyleneglycol, diethyleneglycol, triethyleneglycol, etc.
  • a stabilizer e.g. a polyol or polyalkylene oxide, for example glycerol, polyethyleneglycol, diethyleneglycol, triethyleneglycol, etc.
  • the lipids used as the liposomal membrane forming molecules are typically phospholipids or hydrogenated phospholipids such as natural or synthetic phosphatidylcholines (lecithins) (PC) , phosphatidylethanolamines (PE) , lysolecithins, lysophosphatidylethanolamines, phosphatidylserines (PS) , phosphatidylglycerols (PG) , phosphatidylinositol (PI) , sphingomyelins, cardiolipin, phosphatidic acids (PA) , fatty acids, gangliosides, glucolipids, glycolipids, mono-, di or triglycerides, ceramides or cerebrosides, e.g. liposome membrane forming compounds such as are described in WO-92/21017.
  • PC phosphatidylcholines
  • PE phosphatidylethanolamines
  • PS phosphat
  • the membrane forming lipids may also comprise polymerizable lipids, e.g. methacrylate lipids, thiol and disulphide lipids, dienoate lipids, styryl lipids and diacetylanic lipids as described by Johnston in Liposome Technology Vol. I, Gregoriades Ed., pages 123- 129 (1983) and Singh in Phospholipid Handbook, Cevc Ed., Dekker, pages 233-291 (1993) and references therein.
  • the use of polymerizable lipids in the formation of the liposomes provides one route for increasing liposome stability.
  • Liposomal compositions may be prepared by conventional means, e.g.
  • the continuous phase can if desired be replaced by a continuous phase essentially free of the salicylic acid derivative.
  • compositions of the invention will generally be applied directly to the affected skin site, e.g. by spraying or gentle swabbing.
  • compositions of the invention are especially preferably applied as sprayed solutions, e.g. from pump action or pressurized spray dispensers.
  • Pressurized spray dispensers are especially preferable as access of moisture to the solution during storage before and after first use, and hence hydrolytic breakdown of the salicylic acid derivative, may be avoided.
  • Compositions in this format are novel and form a further aspect of the invention. Viewed from this aspect the invention provides a pressurized spray dispenser containing: an essentially anhydrous alkanolic solution of a physiologically tolerable salicylic acid derivative; a propellant; and optionally but preferably an acemannan.
  • the propellant will be a compound or compound mixture, generally one which is in gaseous form at one atmosphere pressure at 21°C.
  • Halocarbon propellants e.g. CFCs
  • Typical suitable propellants include hydrocarbons such as propane and butane .
  • compositions of the invention are generally low viscosity, easily sprayed liquids, which can be applied without discomfort to the patient.
  • the water content of the alkanol solution is sufficiently low that hydrolysis of the salicylic acid derivative does not occur to a significant extent during storage, e.g. the water content is 2.0% wt or less, preferably 1.0% wt or less.
  • the compositions h'erein described are substantially free - from water.
  • compositions of the invention preferably contain 1 to 30% wt .
  • salicylic acid derivative preferably ASA
  • Aloe vera is preferably present at 0.1 to 4% wt, especially 0.4 to 2% wt, particularly 0.7 to 1.5% wt .
  • the stabilizer if present, is preferably present at 0.5 to 20% wt, especially 2 to 10% wt, more especially 3 to 6% wt .
  • Glycerol is preferably used in this regard.
  • the alcohol solvent preferably anhydrous isopropanol
  • compositions of the invention are preferably administered in dosages of the salicylic acid derivative of 0.005 to 5 mg/cm 2 skin, especially 0.01 to 1.0 mg/cm 2 .
  • compositions of the invention may if desired contain further active ingredients, e.g. antiviral agents, NSAIDs, prostaglandin biosynthesis inhibitors, pain relievers (e.g. lidocaine or other -caine local anaesthetics) , antioxidants, pH modifying agents, skin treatment agents (e.g. ⁇ -hydroxy acids), antimicrobial agents, preservatives, aromas, etc.
  • active ingredients e.g. antiviral agents, NSAIDs, prostaglandin biosynthesis inhibitors, pain relievers (e.g. lidocaine or other -caine local anaesthetics) , antioxidants, pH modifying agents, skin treatment agents (e.g. ⁇ -hydroxy acids), antimicrobial agents, preservatives, aromas, etc.
  • the compositions however will generally preferably be substantially free from Lowry Bronsted acid components, non-alcohol organic solvents (e.g. ethers, halocarbons, etc.) and ointment bases,
  • Aloe vera 1 part by weight
  • a solution according to the invention including aloe vera was applied to a 61 year old male, with acute Herpes zoster in the T 3 dermatome, in a lot of pain.
  • a numeric rating scale from 11- 0, where 11 is great pain
  • after application the following hour he rated it to 4.
  • the skin-inflammation was greatly reduced, and the pain was reduced on the NR3 to 2-3.
  • a solution according to the invention excluding aloe vera was applied to a 37 old female, with acute Herpes simplex on a Labia majora, in pain. After 20 minutes she enjoyed full relief of pain, but she had to apply the spray every hour in 6 hours to get continuous pain relief. The inflammation was totally gone after 25 hours .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

The invention provides an alcoholic solution of a physiologically tolerable salicylic acid derivative and an acemannan for use in topical treatment of herpetic neuralgia. The invention also provides a method of treatment of herpetic neuralgia in a human subject which comprises applying an analgesically effective amount of such a solution to the affected area.

Description

Use
This invention relates to the use of topically applied salicylic acid derivative compositions in the treatment of herpes zoster in humans, in particular to the use of such compositions which are in liquid form and which further contain aloe vera or acemannan, an active component thereof .
The virus herpes zoster is a latent form of the virus responsible for chicken pox and causes the intractable and painful skin eruptions known as shingles which afflict many millions of the elderly in particular. Such painful occurrences are known as herpetic neuralgia, e.g. acute herpetic neuralgia and postherpetic neuralgia.
Aspirin, acetyl salicylic acid (ASA) , is a very well known anti-inflammatory which is normally administered orally in tablet form. While liquid compositions containing ASA, in particular alkanolic solutions of ASA, have been proposed, e.g. for treatment of muscle and joint pain, rheumatism, etc, in recent years liquid ASA formulations have fallen out of favour since ASA is susceptible to hydrolysis producing the irritant salicylic acid.
We have now found that topically applied alcoholic solutions of ASA and acemannan are surprisingly effective in combatting herpetic neuralgia, in particular providing a level of pain relief to the patient .
Thus viewed from one aspect the invention provides an alcoholic solution of a physiologically tolerable salicylic acid derivative and an acemannan for use in topical treatment of herpetic neuralgia.
Viewed from a further aspect the invention provides the use of a physiologically tolerable salicylic acid derivative, an alcohol and an acemannan for the manufacture of a topically applicable medicament for use in the treatment of herpetic neuralgia.
Viewed from a still further aspect the invention provides a method of treatment of herpetic neuralgia in a human subject which method comprises applying to an affected area of the skin of said subject an analgesically effective amount of an alcoholic solution of a physiologically tolerable salicylic acid derivative and an acemannan.
The salicylic acid derivative used according to the invention may be any physiologically tolerable derivative having analgesic properties.
The salicylic acid derivative used in the present invention is preferably ASA, or a physiologically tolerable prodrug (e.g. glycolamide) or salt (e.g. a lysine salt) or ester form thereof or an analog thereof (e.g. a 4 or 5 substituted, for example a 4- and/or 5- nitro and/or methoxy acetyl salicylic acid) .
The salicylic acid derivative, if used in salt form, will have as counterion a physiologically tolerable counterion, preferably an amino acid such as lysine. Other tolerable counterions include sodium and meglumine .
Suitable prodrug forms of ASA include esters which hydrolyse more rapidly in vivo than the acetyl group, e.g. compounds of formula
Figure imgf000003_0001
where R is -CH2-N
-CH2SOCH3 , -CH2S02CH3 , -CH2OOCCH3 , -C^CONR^ , where Rλ is _3 alkyl and R2 is C^ alkyl , 2 -hydroxy-ethyl or -CH2CONH2, e.g. -CH2CON (CH3) 2, -CH2CON (C2H5) 2, -CH2CON (iPr) 2, -CH2CON (CH3) CH2CH2OH and CH2CON (CH3) CH2CONH2.
Acetyl salicylic acid is especially preferred.
The topically applied compositions of the invention also contain acemannan, e.g. in the form of aloe vera. If aloe vera is used, it is preferably used in a pure gel state, although aloe vera in a slightly impure (e.g. at least 98% wt pure) may also be used. Acemannan as such may be used in place of aloe vera.
The compositions of the invention may be in any topically applicable administration form which does not require rubbing of the affected skin, e.g. solutions, emulsions, dispersions, liposomal compositions, sprays, etc. Preferably, the compositions are in the form of solutions or liposome dispersions, particularly solutions .
If desired, the compositions may contain transdermal uptake promoters, such as for example dimethylsulphoxide (DMSO) , dimethylformamide, dimethylacetamide, cycloalkanones, etc. (see US-A- 5164416 and EP-A-435436) .
The compositions contain an alcohol solvent for the salicylic acid derivative, e.g. a Cχ_6 alkanol, preferably a propanol, especially isopropanol.
The compositions of the invention preferably also contain a drying agent, e.g. an inorganic salt in anhydrous or partially hydrated form, so as to minimize the water content of the solvent phase .
The drying agent is preferably a porous material which take up water into its pores or by surface adsorption. Alternatively, it may adsorb water by reaction or by hydration of an anhydrous or partially hydrated form of a crystalline substance with stable hydrated forms. Thus it may for example be a zeolite, e.g. a zeolite with a pore size of 4A or more, for example up to 10A (or where methanol is used as a solvent, a pore size of 3A) . Preferably a zeolite having a pore size of up to 6A, more preferably up to 5A, e.g. 3 to 4A, will be used. Such zeolites are available commercially, e.g. from Fluka. However calcined silica, alumina or silica-alumina or modified starches (e.g. the hydrolysed starch graft copolymers proposed for use in diapers or used in gardening as water retainers - see also GB-A-2009201 and EP-A-74179) , or anhydrous or partially hydrated salts, such as metal sulphates (e.g. magnesium sulphate or sodium sulphate) may alternatively be used. Water retainers, e.g. modified starches, developed in the 1980s by Henkel for diapers and sanitary pads (see the patent publications of Henkel) , and now used in gardening, are typified by "soil-moist", available from Sinclair, Linconshire, UK. The water-adsorbers used should preferably be substantially water free when incorporated into the compositions of the invention. Particle size is preferably 10 to 4000 μm, especially 50 to 2000 μm.
The compositions of the invention further preferably contain a stabilizer, e.g. a polyol or polyalkylene oxide, for example glycerol, polyethyleneglycol, diethyleneglycol, triethyleneglycol, etc.
Where the compositions are in the form of liposome suspensions, the lipids used as the liposomal membrane forming molecules are typically phospholipids or hydrogenated phospholipids such as natural or synthetic phosphatidylcholines (lecithins) (PC) , phosphatidylethanolamines (PE) , lysolecithins, lysophosphatidylethanolamines, phosphatidylserines (PS) , phosphatidylglycerols (PG) , phosphatidylinositol (PI) , sphingomyelins, cardiolipin, phosphatidic acids (PA) , fatty acids, gangliosides, glucolipids, glycolipids, mono-, di or triglycerides, ceramides or cerebrosides, e.g. liposome membrane forming compounds such as are described in WO-92/21017.
The membrane forming lipids may also comprise polymerizable lipids, e.g. methacrylate lipids, thiol and disulphide lipids, dienoate lipids, styryl lipids and diacetylanic lipids as described by Johnston in Liposome Technology Vol. I, Gregoriades Ed., pages 123- 129 (1983) and Singh in Phospholipid Handbook, Cevc Ed., Dekker, pages 233-291 (1993) and references therein. The use of polymerizable lipids in the formation of the liposomes provides one route for increasing liposome stability. Liposomal compositions may be prepared by conventional means, e.g. sonication of a composition comprising the' salicylic acid derivative in solution in an alcohol, and the liposomal membrane forming material. After liposome formation, the continuous phase can if desired be replaced by a continuous phase essentially free of the salicylic acid derivative.
The compositions of the invention will generally be applied directly to the affected skin site, e.g. by spraying or gentle swabbing.
As the affected skin is often extremely tender, the compositions of the invention are especially preferably applied as sprayed solutions, e.g. from pump action or pressurized spray dispensers. Pressurized spray dispensers are especially preferable as access of moisture to the solution during storage before and after first use, and hence hydrolytic breakdown of the salicylic acid derivative, may be avoided. Compositions in this format are novel and form a further aspect of the invention. Viewed from this aspect the invention provides a pressurized spray dispenser containing: an essentially anhydrous alkanolic solution of a physiologically tolerable salicylic acid derivative; a propellant; and optionally but preferably an acemannan.
In such dispensers, the propellant will be a compound or compound mixture, generally one which is in gaseous form at one atmosphere pressure at 21°C. Halocarbon propellants, e.g. CFCs, may be used but non- halocarbons are preferred. Typical suitable propellants include hydrocarbons such as propane and butane .
Thus the compositions of the invention are generally low viscosity, easily sprayed liquids, which can be applied without discomfort to the patient.
By "essentially anhydrous" it is meant that the water content of the alkanol solution is sufficiently low that hydrolysis of the salicylic acid derivative does not occur to a significant extent during storage, e.g. the water content is 2.0% wt or less, preferably 1.0% wt or less. Particularly preferably the compositions h'erein described are substantially free - from water.
The compositions of the invention preferably contain 1 to 30% wt . salicylic acid derivative (preferably ASA) , especially 3 to 20% wt, more especially 4 to 8% wt, particularly 4.5 to 7.0% wt . Aloe vera is preferably present at 0.1 to 4% wt, especially 0.4 to 2% wt, particularly 0.7 to 1.5% wt . The stabilizer, if present, is preferably present at 0.5 to 20% wt, especially 2 to 10% wt, more especially 3 to 6% wt . Glycerol is preferably used in this regard. The alcohol solvent (preferably anhydrous isopropanol) is preferably in present at about 70 to 80% wt . These percentages are relative to the total weight of the composition excluding any drying agent. If a drying agent is used, this is preferably present at 1 to 20% wt, especially 5 to 15% wt relative to the total weight of the composition.
The compositions of the invention are preferably administered in dosages of the salicylic acid derivative of 0.005 to 5 mg/cm2 skin, especially 0.01 to 1.0 mg/cm2.
The compositions of the invention may if desired contain further active ingredients, e.g. antiviral agents, NSAIDs, prostaglandin biosynthesis inhibitors, pain relievers (e.g. lidocaine or other -caine local anaesthetics) , antioxidants, pH modifying agents, skin treatment agents (e.g. α-hydroxy acids), antimicrobial agents, preservatives, aromas, etc. The compositions however will generally preferably be substantially free from Lowry Bronsted acid components, non-alcohol organic solvents (e.g. ethers, halocarbons, etc.) and ointment bases, e.g. containing no more than 2% wt, preferably no more than 0.5% wt in total of such components. In a preferred embodiment the compositions of the invention are substantially free from ethers and/or halogenated hydrocarbons .
All documents referred to herein are hereby incorporated by reference .
The invention will now be described further with reference to the following non-limiting Examples:
EXAMPLE 1
Solution for administration from a pressurized spray dispenser
Acetyl salicylic acid 5.7 parts by weight Isopropanol (anhydrous) 94.3 parts by weight
EXAMPLE 2
Solution for application by spraying
Isopropano1 (anhydrous) 74.8 parts by weight
Glycerol 4.1 parts by weight
Acetyl salicylic acid 5.1 parts by weight
Aloe vera 0.85 parts by weight EXAMPLE 3
Solution for application by spraying
Isopropanol (anhydrous) 81 parts by weight
Glycerol 3 parts by weight
Triethanolamine salicylate 15 parts by weight
Aloe vera 1 part by weight
EXAMPLE 4
Case 1
A solution according to the invention, including aloe vera was applied to a 61 year old male, with acute Herpes zoster in the T 3 dermatome, in a lot of pain. Before application, on a numeric rating scale (from 11- 0, where 11 is great pain) he rated the pain to 7, after application the following hour, he rated it to 4. He applied it almost every hour the following 24 hours. The skin-inflammation was greatly reduced, and the pain was reduced on the NR3 to 2-3.
EXAMPLE 5
Case 2
A solution according to the invention, excluding aloe vera was applied to a 30 year old female, with acute Herpes simplex on lip. She enjoyed total relief after about 15 minutes of application. The inflammation was gone totally after 24 hours. She had used the spray approximately every 2 hours . EXAMPLE 6
Case 3
A solution according to the invention, excluding aloe vera was applied to a 37 old female, with acute Herpes simplex on a Labia majora, in pain. After 20 minutes she enjoyed full relief of pain, but she had to apply the spray every hour in 6 hours to get continuous pain relief. The inflammation was totally gone after 25 hours .

Claims

Claims :
1. An alcoholic solution of a physiologically tolerable salicylic acid derivative and an acemannan for use in topical treatment of herpetic neuralgia.
2. A solution as claimed in claim 1 wherein the salicylic acid derivative is selected from: acetyl salicylic acid, a physiologically tolerable prodrug of acetyl salicylic acid, a salt of acetyl salicylic acid with a physiologically tolerable counterion, an ester form of acetyl salicylic acid or an analogue thereof.
3. A solution as claimed in either of the preceding claims comprising aloe vera as said acemannan.
4. The use of a physiologically tolerable salicylic acid derivative, an alcohol and an acemannan for the manufacture of a topically applicable medicament for use in the treatment of herpetic neuralgia.
5. The use as claimed in claim 4 wherein said medicament is administered by spraying.
6. A method of treatment of herpetic neuralgia in a human subject, which method comprises applying to an affected area of the skin of said subject an analgesically effective amount of a solution as claimed in any of claims 1 to 3.
7. A method as claimed in claim 6 wherein the solution is administered by spraying.
8. A method as claimed in either of claims 6 or 7 wherein the solution is administered in dosages of the salicylic acid derivative of 0.005-5 mg/cm2 skin.
9. A method as claimed in any of claims 6 to 8 wherein said derivative is acetyl salicylic acid.
10. A pressurized spray dispenser containing: an essentially anhydrous alkanolic solution of a physiologically tolerable salicylic acid derivative; a propellant; and optionally but preferably an acemannan.
11. A pressurized spray dispenser as claimed in claim 10 which contains an acemannan.
PCT/GB2001/005380 2000-12-05 2001-12-05 Topical alcoholic solution of a salicylic acid derivative and acemannan Ceased WO2002045687A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01999356A EP1349540A2 (en) 2000-12-05 2001-12-05 Topical alcoholic solution of a salicylic acid derivative and acemannan
AU2002218419A AU2002218419A1 (en) 2000-12-05 2001-12-05 Topical alcoholic solution of a salicylic acid derivative and acemannan

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0029634.3 2000-12-05
GBGB0029634.3A GB0029634D0 (en) 2000-12-05 2000-12-05 Use

Publications (2)

Publication Number Publication Date
WO2002045687A2 true WO2002045687A2 (en) 2002-06-13
WO2002045687A3 WO2002045687A3 (en) 2003-04-10

Family

ID=9904475

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/005380 Ceased WO2002045687A2 (en) 2000-12-05 2001-12-05 Topical alcoholic solution of a salicylic acid derivative and acemannan

Country Status (4)

Country Link
EP (1) EP1349540A2 (en)
AU (1) AU2002218419A1 (en)
GB (1) GB0029634D0 (en)
WO (1) WO2002045687A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1716855A4 (en) * 2004-02-16 2008-06-18 Teikoku Seiyaku Kk Remedy for external use for skin and mucosal injuries caused by viral infection
EP2266533A3 (en) * 2002-06-25 2011-12-14 Acrux DDS Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
FR3130556A1 (en) * 2021-12-16 2023-06-23 L'oreal Use of salicylic acid and/or its derivatives and/or their salts, for increasing or restoring cutaneous tactile perception
WO2025114578A1 (en) 2023-11-29 2025-06-05 Auxesis Pharma Holding Ab (Publ) A composition and use thereof as a medicament

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219548A (en) * 1978-09-01 1980-08-26 The Procter & Gamble Company Topical anti-inflammatory composition
US4942031A (en) * 1988-02-23 1990-07-17 Levin Robert H Compositions containing LYCD and other topically active medicinal ingredients
US5034221A (en) * 1989-06-22 1991-07-23 Rosen Steven E Topical agent and method for the treatment of Pseudofolliculitis barbae
IT1230922B (en) * 1989-06-23 1991-11-08 Giuseppe De Benedittis COMPOSITION FOR THE TREATMENT OF ACUTE HERPETIC NEVRALGIA AND POST-HERPETIC NEVRALGIA
EP0639068A1 (en) * 1992-05-05 1995-02-22 The Procter & Gamble Company Acne treating composition
US5736126A (en) * 1996-03-15 1998-04-07 Van Engelen; H. Wayne Liquid transdermal analgesic
GB9914582D0 (en) * 1999-06-22 1999-08-25 Us Analgesic Group Inc Composition

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2266533A3 (en) * 2002-06-25 2011-12-14 Acrux DDS Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
US8357393B2 (en) 2002-06-25 2013-01-22 Acrux Dds Pty Ltd. Transdermal delivery rate control using amorphous pharmaceutical compositions
US8784878B2 (en) 2002-06-25 2014-07-22 Acrux DDS Pty Ltc. Transdermal delivery rate control using amorphous pharmaceutical compositions
EP1534235B1 (en) * 2002-06-25 2016-07-27 Acrux DDS Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
EP1716855A4 (en) * 2004-02-16 2008-06-18 Teikoku Seiyaku Kk Remedy for external use for skin and mucosal injuries caused by viral infection
FR3130556A1 (en) * 2021-12-16 2023-06-23 L'oreal Use of salicylic acid and/or its derivatives and/or their salts, for increasing or restoring cutaneous tactile perception
WO2025114578A1 (en) 2023-11-29 2025-06-05 Auxesis Pharma Holding Ab (Publ) A composition and use thereof as a medicament

Also Published As

Publication number Publication date
GB0029634D0 (en) 2001-01-17
WO2002045687A3 (en) 2003-04-10
EP1349540A2 (en) 2003-10-08
AU2002218419A1 (en) 2002-06-18

Similar Documents

Publication Publication Date Title
ES2299258T3 (en) SPONGE COMPOUND.
ES2207023T3 (en) COMPOSITIONS THAT INCLUDE A COMBINATION OF A FREE SPPHINGOID BASE AND A CERAMIDE AND USE OF THE SAME.
Goh et al. Formulation of diclofenac for dermal delivery
JP4555111B2 (en) With improved deformability, including at least three amphiphiles for improved transport through a semipermeable barrier and for non-invasive drug utilization in vivo, especially through the skin Agglomerates
US5045559A (en) Treatment of skin disorders
JP2000513706A (en) Skin care formulations and methods
ITMI20070644A1 (en) TOPIC COMPOSITIONS INCLUDING MAGALDRATE
WO2002045687A2 (en) Topical alcoholic solution of a salicylic acid derivative and acemannan
WO1998010768A1 (en) Antiviral compositions
ZA200304635B (en) Hypoallergenic and non-irritant skin care formulations.
US8529915B2 (en) (R)-(-)-1,2-propanediol compositions and methods
ITRM930365A1 (en) USE OF L-CARNITINE ESTERS ON OXYDRIDE WITH AROMATIC ACIDS TO PRODUCE PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES.
KR100527346B1 (en) multilamellar emulsion cosmetics containing pseudoceramides
DE69206913T2 (en) Formulations for the treatment of vaginal dryness
WO2011138364A1 (en) Topical composition and use thereof for the prophylaxis and the treatment of defects connected to inflammatory dermopathies
US20080076831A1 (en) Hemorrhoid reliever and method of use
EP1146844B1 (en) Membrane lipid compositions
ES2225837T3 (en) 2,3-DIARIL-1-BENZOPIRANS FOR THE TREATMENT OF DERMATITIS.
US20150105349A1 (en) (R)-(-)-1,2-propanediol compositions and methods
KR102015890B1 (en) Polysaccharide liquid crystal composition and manufacturing method thereof and cosmetic composition comprising the same
EP0834312B1 (en) Topical medicament containing diclofenac
CA2299298A1 (en) Compositions for nasal administration
EP1341515B1 (en) Water-free skin care formulations comprising micronized urea and method of manufacturing the same
EP4342450A1 (en) Hydroalcoholic topical diclofenac formulations
EP1107766B1 (en) Use of lithium gluconate in the preparation of a medicament for treating herpes and seborrheic dermatitis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001999356

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002218419

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2001999356

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001999356

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP